REFERENCES
- Heit H. Addiction, physical dependence, and tolerance: precise definitions to help clinicians evaluate and treat chronic pain patients. J Pain Palliat Care Pharmacother. 2003;17:15–29.
- Albutt C. On the abuse of hypodermic injections of morphia. Practitioner. 1870;5:327–331.
- Rossbach M. Ueber die Gewoehnung an Gifte. Pflugers Archieve Gesamte Physiologie des Menschen. 1880;21:213–225.
- World Health Organization. Cancer Pain Relief: With A Guide to Opioid Availability. 2nd ed. Geneva, Switzerland: World Health Organization; 1996.
- World Health Organization and International Association for the Study of Pain. Cancer Pain Relief and Palliative Care in Children. Geneva, Switzerland: World Health Organization; 1998.
- American Academy of Pain Medicine, American Pain Society. The use of opioids for the treatment of chronic pain: A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13:6–8.
- Tverskoy M, Oz Y, Isakson, A, Finger J, Bradley EL Jr, Kissin, I. Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia. Anesth Analg. 1994;78: 205–209.
- Stubhaug A, Breivik H, Eide PK, Krunen M, Foss A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand. 1997;41:1124–1132.
- Weinbroum AA. A single small dose of posteroperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg. 2003;96:789–795.
- Salpeter SR, Buckley JS, Bruera E. The use of very low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med. 2013;16:616–622.
- Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm. 2009;66:825–833.
- Ray WA, Chung CP, Murray KT, Cooper WO, Hall K, Stein CM. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med. 2015;175:420–427. doi: 10.1001/jamainternmed.2014.6294.
- Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479–496.
- Lee M, Silverman S, Hansen H, Patel V, Manckikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14:145–161.
- Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570–587.
- Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff S. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med. 2009;10:829–839.
- Smith HS, Elliott JA. Opioid-induced androgen deficiency (OPIAD). Pain Physician. 2012;15:ES145–ES156.
- Basaria S, Travison T, Alford D, et al. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015;156:280–288.
- Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2012;(11):CD003351.
- Roberts SB, Wozencraft CP, Coyne PJ, Smith TJ. Dexmedetomidine as an adjuvant analgesic for intractable cancer pain. J Palliat Med. 2011;14:371–373.
- Rork JF, Berde CB, Goldstein RD. Regional anesthesia approaches to pain management in pediatric palliative care: a review of current knowledge. J Pain Symptom Manage. 2013;46:859–873.
- Anghelescu DL, Faughnan LG, Baker JN, Yang J, Kane JR. Use of epidural and periperhal nerve blocks at the end of life in children and young adults with cancer: the collaboration between a pain service and a palliative care service. Paediatr Anaesth. 2010;20:1070–1077.
- Smith TJ, Coyne PJ, Staats PS, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol. 2005;15:825–883.